Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Reta an investigational triple-agonist synthetic peptide developed by Eli Lilly and Company that activates GLP-1, GIP, and glucagon receptors. Clinical trials show it produces major reductions in body weight (up to ~24–28%) and improves metabolic health, though it is not yet FDA-approved.
Reta an investigational triple-agonist synthetic peptide developed by Eli Lilly and Company that activates GLP-1, GIP, and glucagon receptors. Clinical trials show it produces major reductions in body weight (up to ~24–28%) and improves metabolic health, though it is not yet FDA-approved.